Payment overview · 2025
General Payments
$577.98
19 reported records · 11 companies
Healthcare provider profile · identity verified
Abdul Hamid Sofi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PERRY, FL · NPI 1205885613
Verified facts
What the public records show
CMS Open Payments records show Abdul Hamid Sofi, M.D. received $577.98 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.15 | 27.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.00 | 25.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.25 | 10.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.77 | 8.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.41 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.73 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.83 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.01 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.98 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.95 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.90 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $577.98 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $160.15 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.25 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 154 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 635 | 105 |
| Alprazolam | Alprazolam | 623 | 94 |
| Zolpidem Tartrate | Zolpidem Tartrate | 442 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 139 |
| Tramadol Hcl | Tramadol Hcl | 398 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 130 |
| Omeprazole | Omeprazole | 334 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 103 |
| Losartan Potassium | Losartan Potassium | 299 | 104 |
| Gabapentin | Gabapentin | 277 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 95 |
| Furosemide | Furosemide | 246 | 91 |
| Lisinopril | Lisinopril | 237 | 76 |
| Metformin Hcl | Metformin Hcl | 227 | 69 |
| Oxycodone Hcl | Oxycodone Hcl | 223 | 25 |
| Pregabalin | Pregabalin | 206 | 43 |
| Celecoxib | Celecoxib | 195 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 61 |
| Eliquis | Apixaban | 154 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 22 |
| Simvastatin | Simvastatin | 141 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 30 |
| Montelukast Sodium | Montelukast Sodium | 140 | 50 |
| Lorazepam | Lorazepam | 138 | 26 |
| Carvedilol | Carvedilol | 133 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 49 |
| Meloxicam | Meloxicam | 131 | 51 |
| Jardiance | Empagliflozin | 130 | 30 |
| Clonazepam | Clonazepam | 122 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 33 |
| Potassium Chloride | Potassium Chloride | 106 | 35 |
| Cefdinir | Cefdinir | 105 | 79 |
| Temazepam | Temazepam | 105 | 15 |
| Famotidine | Famotidine | 94 | 29 |
| Clonidine Hcl | Clonidine Hcl | 93 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 23 |
| Glimepiride | Glimepiride | 92 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 33 |
| Trazodone Hcl | Trazodone Hcl | 91 | 28 |
| Alendronate Sodium | Alendronate Sodium | 87 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 28 |
| Ozempic | Semaglutide | 81 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 26 |
| Prednisone | Prednisone | 79 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 28 |
| Allopurinol | Allopurinol | 73 | 29 |
| Azithromycin | Azithromycin | 65 | 47 |
| Januvia | Sitagliptin Phosphate | 65 | 19 |
| Warfarin Sodium | Warfarin Sodium | 63 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 14 |
| Eszopiclone | Eszopiclone | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 56 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 56 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 16 |
| Sertraline Hcl | Sertraline Hcl | 51 | 20 |
| Fenofibrate | Fenofibrate | 50 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 39 |
| Ibuprofen | Ibuprofen | 46 | 14 |
| Ramipril | Ramipril | 46 | 14 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Finasteride | Finasteride | 43 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 14 |
| Diazepam | Diazepam | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 38 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 34 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 13 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Linzess | Linaclotide | 32 | 13 |
| Acyclovir | Acyclovir | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 29 |
| Baclofen | Baclofen | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Lactulose | Lactulose | 23 | 13 |
| Atenolol | Atenolol | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 17 |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dexilant | Dexlansoprazole | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | 11 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Xanax | Alprazolam | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Carbinoxamine Maleate | Carbinoxamine Maleate | 13 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $577.98 · 19 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, ELIQUIS, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TRINTELLIX, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error